The transversal statistical study, involving 38 infants, distributed into three groups, showed a significant difference, using the Kruskal-Wallis test for the standing position, between the group of preterm infants with gestacional age between 32 and 36 weeks and the group of at term infants, in the 4 th and 5 th month of age. The longitudinal statistical study, considering 24 infants that never missed na evaluation and the preterm infants grouped showed significant difference, using the Analysis of Variance, Studies of chemokines in cerebrospinal fluid (CSF) of patients with active multiple sclerosis have indicated that specific chemokines may develop an important role in the pathogenesis of the disease. Chemokines and its receptors have been associated with the migration of lymphocytes, monocytes, eosinophils, basophils and neutrophils under physiological and pathological conditions and have been considered important targets for investigation.
We have investigated the expression of two biologically important chemokines (CCL2 and CXCL10) in CSF and serum of 14 patients with relapsing multiple sclerosis (MS) and 14 controls with noninflammatory CSF and 14 healthy individual's serum controls. We have also investigated the expression of these chemokines and the clinical alterations measured through Expanded Disability Status Scale (EDSS), Neurologic Rating Scale (NRS) and Ambulatory Index (AI) for MS before and after the treatment with intravenous methylprednisolone (IVMP) for five days.
In the admission, CCL2 concentrations were lower in MS patients than in controls; however, CXCL10 concentrations have demonstrated being higher in MS patients than in controls. The treatment has significantly changed the CCL2 and CXCL10 levels in CSF before and after the treatment. There was a statistically significant scores improvement of all the scales applied (EDSS, NRS and AI) soon after the end of the treatment.
Our results indicate that higher CXCL10 concentrations in the CSF and lower CCL2 concentrations are associated with relapses in multiple sclerosis.
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